Estrógeno potenciado en el tratamiento homeopático del dolor pélvico asociado a endometriosis: un estudio aleatorizado, doble ciego, controlado con placebo, de 24 semanas / Potentiated estrogen in the homeopathic treatment of pelvic pain associated with endometriosis: a 24-week randomized, double-blind, placebo-controlled study

Evaluar la eficacia y seguridad del estrógeno potenciado en comparación con el placebo en el tratamiento homeopático del dolor pélvico asociado a endometriosis (EAPP, por sus siglas en inglés). Diseño del estudio: El presente fue un estudio clínico aleatorizado, doble ciego, controlado con placebo, de 24 semanas, el cual incluyó a 50 mujeres de entre 18 y 45 años de edad con diagnóstico de endometriosis infiltrante profunda con base en ultrasonido transvaginal o imágenes de resonancia magnética después de preparación intestinal, así como puntaje ≥ 5 en una escala visual analógica (VAS: rango de 0 a 10 puntos) para el dolor pélvico asociado con la endometriosis. Se administró estrógeno potenciado (12cH, 18cH y 24cH) o placebo dos veces al día por vía oral. La medida principal de resultado fue el cambio en la severidad de los puntajes parcial y global de EAPP (VAS) de la línea basal a la semana 24, determinada como la diferencia en el puntaje medio de cinco modalidades de dolor pélvico crónico (dismenorrea, dispareunia profunda, dolor pélvico no cíclico, dolor intestinal cíclico y/o dolor urinario cíclico). Las medidas secundarias de resultado fueron la diferencia media de puntaje para la calidad de vida evaluada con el Cuestionario de Salud SF-36, los síntomas de depresión en el Inventario de la Depresión de Beck (BDI) y los síntomas de ansiedad en el Inventario de Ansiedad de Beck (BAI). Resultados: El puntaje global de EAPP (VAS: rango de 0 a 50 puntos) se redujo en 12.82 (p < 0.001) en el grupo tratado con estrógeno potenciado de la línea basal a la semana 24. El grupo que utilizó estrógeno potenciado también presentó una reducción en el puntaje parcial (VAS: rango de 0 a 10 puntos) en tres modalidades de EAPP: dismenorrea (3.28; p < 0.001), dolor pélvico no cíclico (2.71; p = 0.009) y dolor intestinal cíclico (3.40; p < 0.001). El grupo de placebo no mostró cambio significativo alguno en los puntajes global o parcial de EAPP. Además, el grupo de estrógeno potenciado mostró un mejoramiento significativo en tres de ocho ámbitos de SF-36 (dolor de cuerpo, vitalidad y salud mental) y síntomas de depresión (BDI). El grupo de placebo no mostró un mejoramiento significativo a este respecto. Estos resultados demuestran la superioridad del estrógeno potenciado sobre el placebo. Se asociaron pocos eventos adversos con el estrógeno potenciado. Conclusiones: El estrógeno potenciado (12cH, 18cH y 24cH) en dosis de 3 gotas dos veces al día durante 24 semanas fue significativamente más efectivo que el placebo para reducir el dolor pélvico asociado con la endometriosis. Registro del estudio clínico: ClinicalTrials.gov Identificador: https://clinicaltrials.gov/show/NCT02427386.

To evaluate the efficacy and safety of potentized estrogen compared to placebo in homeopathic treatment of endometriosis-associated pelvic pain (EAPP). Study design: The present was a 24-week, randomized, doubleblind, placebocontrolled trial that included 50 women aged 18-45 years old with diagnosis of deeply infiltrating endometriosis based on magnetic resonance imaging or transvaginal ultrasound after bowel preparation, and score ≥ 5 on a visual analogue scale (VAS: range 0 to 10 points) for endometriosis-associated pelvic pain. Potentized estrogen (12cH, 18cH and 24cH) or placebo was administered twice daily per oral route. The primary outcome measure was change in the severity of EAPP global and partial scores (VAS) from baseline to week 24, determined as the difference in the mean score of five modalities of chronic pelvic pain (dysmenorrhea, deep dyspareunia, non-cyclic pelvic pain, cyclic bowel pain and/or cyclic urinary pain). The secondary outcome measures were mean score difference for quality of life assessed with SF-36 Health Survey Questionnaire, depression symptoms on Beck Depression Inventory (BDI), and anxiety symptoms on Beck Anxiety Inventory (BAI). Results: The EAPP global score (VAS: range 0 to 50 points) decreased by 12.82 (p < 0.001) in the group treated with potentized estrogen from baseline to week 24. Group that used potentized estrogen also exhibited partial score (VAS: range 0 to 10 points) reduction in three EAPP modalities: dysmenorrhea (3.28; p < 0.001), non-cyclic pelvic pain (2.71; p = 0.009), and cyclic bowel pain (3.40; p < 0.001). Placebo group did not show any significant changes in EAPP global or partial scores. In addition, the potentized estrogen group showed significant improvement in three of eight SF-36 domains (bodily pain, vitality and mental health) and depression symptoms (BDI). Placebo group showed no significant improvement in this regard. These results demonstrate superiority of potentized estrogen over placebo. Few adverse events were associated with potentized estrogen. Conclusions: Potentized estrogen (12cH, 18cH and 24cH) at a dose of 3 drops twice daily for 24 weeks was significantly more effective than placebo for reducing endometriosis-associated pelvic pain.

Assessment of weight gain and control of parasitism by Rhipicephalus microplus in dairy cattle in the field using organosynthetic parasiticide, phytotherapics and homeopathy / Avaliação do ganho de peso e controle do parasitismo por Rhipicephalus microplus em bovinos leiteiros a campo usando parasiticida organosintético, fitoterápicos e homeopatia

The goal of this research was to compare the effect of the following products on dairy cattle, parasitized by Rhipicephalus microplus: organosynthetics - Clorfenvinfós and Ivermectina (OG); phytotherapics - Eucalyptus oil (EG) and Neem cake (NG); Homeopathy (HG); The control group (CG) received no treatment. Infestation was by R. microplus (MIC) and weight gain (GP) were evaluated. The study included 60 animals (5 groups) from ­ Dutch / Zebu, aged between 25-44 months and initial weight between 211-477kg. EG and NG showed MIC 84.9% and 14.0% greater than CG, respectively (P <0.05; P = 0). HG and OG had MIC less than CG 24.4% and 16.9%, respectively (P<0.05; P <0.05). EG, NG and OG obtained GP lower than CG in 7.9%, 8.9% and 8.06% (P <0.05) respectively. The HG GP was 4.9% higher (P <0.05) than CG. This was the first research to prove parasitism control by R. microplus in a field test, using homeopathy. The methodology for choosing Homeopathy for the control of enzooties, developed and tested for the first time in this study, proved to be adequate and efficient, opening the possibility for establishing a new methodology for strategic control of parasitism by R. microplus.(AU)

O objetivo desta pesquisa foi comparar o efeito dos seguintes produtos sobre bovinos leiteiros, parasitados por Rhipicephalus microplus: organossintéticos - clorfenvinfós e ivermectina (OG); fitoterápicos - óleo de eucalipto (EG) e torta de Neem (NG) e homeopatia (HG). O grupo controle (CG) não recebeu tratamento. Foram avaliados infestação por R. microplus (MIC) e ganho de peso/grupo (GP) em 60 animais (5 grupos), a partir de ­ holandês/zebu, com idade entre 25 e 44 meses e peso inicial entre 211 e 477kg. EG e NG apresentaram MIC 84,9% e 14,0% maior que CG, respectivamente (P<0,05; P=0). HG e OG apresentaram MIC menor que CG 24,4% e 16,9%, respectivamente (P<0,05; P<0,05). EG, NG e OG obtiveram GP menor que CG em 7,9%, 8,9% e 8,06% (P<0,05), respectivamente. O GP do HG foi 4,9% maior (P<0,05) que o CG. Esta foi a primeira pesquisa a comprovar controle do parasitismo por R. microplus em teste a campo, usando homeopatia. A metodologia para escolha de medicamentos homeopáticos para controle de enzootias, desenvolvida e testada pela primeira vez neste estudo, mostrou-se adequada e eficiente, abrindo a possibilidade para estabelecimento de nova metodologia para controle estratégico do parasitismo por R. microplus.(AU)

Enuresis no orgánica tratada con medicamentos homeopáticos / Non-organic nocturnal enuresis treated with homeopathic drugs

RESUMEN Introducción: la enuresis nocturna en niños es motivo de consulta frecuente. Objetivo: evaluar la evolución clínica en pacientes pediátricos de cinco a 18 años, con enuresis nocturna no orgánica, tratados con medicamentos homeopáticos. Métodos: se realizó un estudio cuasi-experimental de intervención. La muestra se conformó de forma intencional por 327 pacientes con enuresis de la consulta de Homeopatía del Hospital Provincial Pediátrico Docente, "Pepe Portilla", de enero del 2015 a enero 2018. En el procesamiento se utilizaron herramientas descriptivas como tablas de frecuencias y cálculo porcentual. Además de la prueba Kolmogorov Smirnov para comparar tendencia de variables entre dos grupos independientes. Resultados: predominaron los niños entre cinco a 11 años del sexo masculino. En ambos grupos prevaleció la enuresis primaria, la incapacidad para despertar y los antecedentes familiares de enuresis. En el grupo estudio, 76,1 % tuvo respuesta completa al tratamiento, solo un caso no tuvo respuesta; en el grupo control solo 8,3 % de los pacientes obtuvo respuesta completa. Conclusiones: la Homeopatía es una modalidad terapéutica útil en el tratamiento de la enuresis no orgánica en niños.

ABSTRACT Introduction: nocturnal enuresis in children is a frequent reason for attending the doctor's office. Objective: to evaluate the clinical evolution in pediatric patients from 5 to 18 years old with non-organic nocturnal enuresis treated with homeopathic drugs. Methods: a quasi-experimental intervention study was conducted. The sample intentionally comprised 327 patients with nocturnal enuresis from the Homeopathy Clinic at Pepe Portilla Provincial Pediatric Teaching Hospital, from January 2015 to January 2018. Descriptive tools such as frequency tables and percentage calculation were applied to process the data. In addition to the Kolmogorov Smirnov test to compare the trend of the variables between two independent groups. Results: male children between 5 and 11 years old predominated. In both groups, primary enuresis, the characteristic inability to wake up and family history of enuresis prevailed. In the study group, 76.1% had complete response to treatment, only one case had no response, in the control group only 8.3% of patients had complete response. Conclusions: homeopathy is a useful therapeutic modality in the treatment of non-organic nocturnal enuresis in children.

Tratamiento homeopático de los condilomas acuminados en niños en hospital pediátrico pinareño / Homeopathic treatment of condyloma acuminata in children Pediatric pinareño

RESUMEN Introducción: se ha identificado un incremento de pacientes pediátricos con condilomas acuminados. Objetivo: evaluar la efectividad de los medicamentos homeopáticos en el tratamiento de los condilomas acuminados en niños de un mes a 18 años, en hospital pediátrico pinareño entre los años 2014 y 2015. Métodos: se realizó un estudio descriptivo longitudinal y prospectivo a un universo muestral de 33 niños, remitidos por el Dermatólogo a la consulta de Medicina Bioenergética y Natural del Hospital Pediátrico Provincial Docente Pepe Portilla de Pinar del Río, Cuba, durante los años 2014-2015, seguidos de forma evolutiva hasta el 2018. Se les aplicaron medicamentos homeopáticos seleccionados de forma tópica y sistémica. Resultados: no existió predominio de sexo, la edad más representada fue de 13-18 años, y la localización más frecuente fue genital con morfología clínica predominante coliflor, el modo de transmisión más frecuente fue por contacto sexual. En cuatro pacientes se corroboró abuso sexual, en el resto de los casos por hetero inoculación. La evolución fue satisfactoria con la aparición de lesiones en el tercer año de su seguimiento. Conclusiones: las verrugas ano genitales son un reto para el pediatra y el dermatólogo pedíatra, sobre todo sus mecanismos de transmisión. Los medicamentos homeopáticos resultaron eficaces en el tratamiento de los condilomas acuminados en niños.

ABSTRACT Introduction: an increase in pediatric patients with condyloma acuminata has been identified. Objective: to assess the effectiveness of homeopathic medicines in the treatment of condyloma acuminata in children from 1 month to 18 years at Pepe Portilla Pediatric Provincial Teaching Hospital in Pinar del Río between the years 2014 and 2015. Methods: a longitudinal and prospective descriptive study was carried out on a sampling target group of 33 children, referred by the Dermatologist to the Bioenergetic and Natural Medicine consultation at Pepe Portilla Pediatric Provincial Teaching Hospital in Pinar del Río, Cuba, during the years 2014-2015, performing a follow-up until 2018. Topical and systemic homeopathic medicines were chosen to apply to them. Results: there was no predominance of gender, the age most represented was 13-18 years, and the most frequent location was genital regions, predominantly cauliflower clinical morphology, the most frequent type of transmission was by sexual contact. In four patients sexual abuse was corroborated, in the rest of the cases by hetero inoculation, the evolution was satisfactory with the appearance of lesions in the third year of their follow-up. Conclusions: genital-anal warts are a challenge for the pediatricians and pediatric dermatologists; basically because of their mechanisms of transmission. Homeopathic medicines were effective in the treatment of condyloma acuminata in children.

Potentized estrogen in homeopathic treatment of endometriosis-associated pelvic pain: A 24-week, randomized, double-blind, placebo-controlled study.

OBJECTIVE: To evaluate the efficacy and safety of potentized estrogen compared to placebo in homeopathic treatment of endometriosis-associated pelvic pain (EAPP). STUDY DESIGN: The present was a 24-week, randomized, double-blind, placebo-controlled trial that included 50 women aged 18-45 years old with diagnosis of deeply infiltrating endometriosis based on magnetic resonance imaging or transvaginal ultrasound after bowel preparation, and score≥5 on a visual analogue scale (VAS: range 0 to 10) for endometriosis-associated pelvic pain. Potentized estrogen (12cH, 18cH and 24cH) or placebo was administered twice daily per oral route. The primary outcome measure was change in the severity of EAPP global and partial scores (VAS) from baseline to week 24, determined as the difference in the mean score of five modalities of chronic pelvic pain (dysmenorrhea, deep dyspareunia, non-cyclic pelvic pain, cyclic bowel pain and/or cyclic urinary pain). The secondary outcome measures were mean score difference for quality of life assessed with SF-36 Health Survey Questionnaire, depression symptoms on Beck Depression Inventory (BDI), and anxiety symptoms on Beck Anxiety Inventory (BAI). RESULTS: The EAPP global score (VAS: range 0 to 50) decreased by 12.82 (P<0.001) in the group treated with potentized estrogen from baseline to week 24. Group that used potentized estrogen also exhibited partial score (VAS: range 0 to 10) reduction in three EAPP modalities: dysmenorrhea (3.28; P<0.001), non-cyclic pelvic pain (2.71; P=0.009), and cyclic bowel pain (3.40; P<0.001). Placebo group did not show any significant changes in EAPP global or partial scores. In addition, the potentized estrogen group showed significant improvement in three of eight SF-36 domains (bodily pain, vitality and mental health) and depression symptoms (BDI). Placebo group showed no significant improvement in this regard. These results demonstrate superiority of potentized estrogen over placebo. Few adverse events were associated with potentized estrogen. CONCLUSIONS: Potentized estrogen (12cH, 18cH and 24cH) at a dose of 3 drops twice daily for 24 weeks was significantly more effective than placebo for reducing endometriosis-associated pelvic pain. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02427386.

Araceae: grande família botânica de poucos remédios homeopáticos / Araceae: great botanical family of few homeopathic remedies

Na prática homeopática, não são raras as vezes em que ao procurar solucionar as angústias dos pacientes, encontramos remédios pequenos , ou, pouco conhecidos , e os deixamos de lado escolhendo outro que nos é mais familiar, muitas vezes retardando a solução que buscávamos.A família Araceae, pouco conhecida, pelo levantamento de diversas Matérias Medicas, pode ampliar os recursos que precisamos ter, para cura dos pacientes que nos procuram. (AU)

In homeopathic practice, it is not uncommon to find small or little-known remedies when trying to solve patient’s’ anxieties, and we leave them aside by choosing another that is more familiar to us, often delaying the solution we were looking for.The Araceae family, little known by the survey of various medical materials, can expand the resources that we need to have, to cure the patients who are looking for us. (AU)

Estrogênio potencializado no tratamento homeopático da dor pélvica associada à endometriose: Um estudo de 24 semanas, randomizado, duplocego e placebo-controlado / Estrogen potentiated in the homeopathic treatment of endometriosis-associated pelvic pain: A 24-week, randomized, double-blind, placebo-controlled study

Objetivo: Avaliar a eficácia e a segurança do estrogênio potencializado em comparação com o placebo no tratamento homeopático da dor pélvica associada à endometriose (DPAE). Desenho do estudo: Ensaio randomizado, duplo-cego e placebocontrolado de 24 semanas de duração, que incluiu 50 mulheres com idade entre 18-45 anos de idade, diagnóstico de endometriose infiltrativa profunda com base em ressonância magnética nuclear ou ultrassonografia transvaginal após preparo intestinal e escore ≥ 5 na escala analógica visual (EAV: intervalo de 0 a 10 pontos) para DPAE. Estrogênio potencializado (12cH, 18cH e 24cH) ou placebo foi administrado 2 vezes ao dia por via oral. A medida de desfecho primário foi a mudança na severidade da DPAE com base no escore global e parcial (EAV) entre as semanas 0-24, determinado pela diferença entre a pontuação média de 5 modalidades de dor pélvica crônica (dismenorreia, dispareunia de profundidade, dor pélvica acíclica, dor intestinal cíclica e/ou dor urinária cíclica). Os desfechos secundários foram: diferença nos escores médios para qualidade de vida (SF-36), sintomas de depressão (Inventário de Depressão de Beck, IDB) e sintomas de ansiedade (Inventário de Ansiedade de Beck, IAB). [...]O grupo placebo não mostrou qualquer melhora significativa nesses desfechos secundários. Esses resultados demonstraram a superioridade do estrogênio potencializado em comparação ao placebo. Alguns efeitos adversos foram associados com o estrogênio dinamizado. Conclusões: Estrogênio potencializado (12cH, 18cH e 24cH) na dose de 3 gotas 2 vezes ao dia durante 24 semanas foi significativamente mais eficaz que o placebo na redução da dor pélvica associada à endometriose.Registro do estudo: ClinicalTrials.gov Identificador: NCT02427386. (AU)

Objective: To evaluate the efficacy and safety of potentized estrogen compared to placebo in homeopathic treatment of endometriosis-associated pelvic pain (EAPP). Study design: The present was a 24-week, randomized, double-blind, placebocontrolled trial that included 50 women aged 18-45 years old with diagnosis of deeply infiltrating endometriosis based on magnetic resonance imaging or transvaginal ultrasound after bowel preparation, and score ≥ 5 on a visual analogue scale (VAS: range 0 to 10 points) for endometriosis-associated pelvic pain. Potentized estrogen (12cH, 18cH and 24cH) or placebo was administered twice daily per oral route. The primary outcome measure was change in the severity of EAPP global and partial scores (VAS) from baseline to week 24, determined as the difference in the mean score of five modalities of chronic pelvic pain (dysmenorrhea, deep dyspareunia, non-cyclic pelvic pain, cyclic bowel pain and/or cyclic urinary pain). The secondary outcome measures were mean score difference for quality of life assessed with SF-36 Health Survey Questionnaire, depression symptoms on Beck Depression Inventory (BDI), and anxiety symptoms on Beck Anxiety Inventory (BAI). [...] Placebo group did not show any significant changes in EAPP global or partial scores. In addition, the potentized estrogen group showed significant improvement in three of eight SF-36 domains (bodily pain, vitality and mental health) and depression symptoms (BDI). Placebo group showed no significant improvement in this regard. These results demonstrate superiority of potentized estrogen over placebo. Few adverse events were associated with potentized estrogen. Conclusions: Potentized estrogen (12cH, 18cH and 24cH) at a dose of 3 drops twice daily for 24 weeks was significantly more effective than placebo for reducing endometriosis-associated pelvic pain. Trial registration: ClinicalTrials.gov Identifier: NCT02427386. (AU)fier: NCT02427386. (AU)

Potentized estrogen in homeopathic treatment of endometriosis-associatedpelvic pain: A 24-week, randomized, double-blind, placebo-controlled study

Objective: To evaluate the efficacy and safety of potentized estrogen compared to placebo in homeopathic treatment of endometriosis-associated pelvic pain (EAPP). Study design: The present was a 24-week, randomized, double-blind, placebocontrolled trial that included 50 women aged 18-45 years old with diagnosis of deeply infiltrating endometriosis based on magnetic resonance imaging or transvaginal ultrasound after bowel preparation, and score ≥ 5 on a visual analogue scale (VAS: range 0 to 10 points) for endometriosis-associated pelvic pain. Potentized estrogen (12cH, 18cH and 24cH) or placebo was administered twice daily per oral route. The primary outcome measure was change in the severity of EAPP global and partial scores (VAS) from baseline to week 24, determined as the difference in the mean score of five modalities of chronic pelvic pain (dysmenorrhea, deep dyspareunia, non-cyclic pelvic pain, cyclic bowel pain and/or cyclic urinary pain). The secondary outcome measures were mean score difference for quality of life assessed with SF-36 Health Survey Questionnaire, depression symptoms on Beck Depression Inventory (BDI), and anxiety symptoms on Beck Anxiety Inventory (BAI). Results: The EAPP global score (VAS: range 0 to 50 points) decreased by 12.82 (p< 0.001) in the group treated with potentized estrogen from baseline to week 24. Group that used potentized estrogen also exhibited partial score (VAS: range 0 to 10 points) reduction in three EAPP modalities: dysmenorrhea (3.28; p< 0.001), non-cyclic pelvic pain (2.71; p= 0.009), and cyclic bowel pain (3.40; p< 0.001). Placebo group did not show any significant changes in EAPP global or partial scores. [...] Conclusions: Potentized estrogen (12cH, 18cH and 24cH) at a dose of 3 drops twice daily for 24 weeks was significantly more effective than placebo for reducing endometriosis-associated pelvic pain. Trial registration: ClinicalTrials.gov Identifier: https://clinicaltrials.gov/show/NCT02427386. (AU)

Estrogênio potencializado no tratamento homeopático da dor pélvica associada à endometriose: Um estudo de 24 semanas, randomizado, duplocego e placebo-controlado / Potentized estrogen in homeopathic treatment of endometriosis-associatedpelvic pain: A 24-week, randomized, double-blind, placebo-controlled study

Objetivo: Avaliar a eficácia e a segurança do estrogênio potencializado em comparação com o placebo no tratamento homeopático da dor pélvica associada à endometriose (DPAE). Desenho do estudo: Ensaio randomizado, duplo-cego e placebocontrolado de 24 semanas de duração, que incluiu 50 mulheres com idade entre 18-45 anos de idade, diagnóstico de endometriose infiltrativa profunda com base em ressonância magnética nuclear ou ultrassonografia transvaginal após preparo intestinal e escore ≥ 5 na escala analógica visual (EAV: intervalo de 0 a 10 pontos) para DPAE. Estrogênio potencializado (12cH, 18cH e 24cH) ou placebo foi administrado 2 vezes ao dia por via oral. A medida de desfecho primário foi a mudança na severidade da DPAE com base no escore global e parcial (EAV) entre as semanas 0-24, determinado pela diferença entre a pontuação média de 5 modalidades de dor pélvica crônica (dismenorreia, dispareunia de profundidade, dor pélvica acíclica, dor intestinal cíclica e/ou dor urinária cíclica). Os desfechos secundários foram: diferença nos escores médios para qualidade de vida (SF-36), sintomas de depressão (Inventário de Depressão de Beck, IDB) e sintomas de ansiedade (Inventário de Ansiedade de Beck, IAB). [...]O grupo placebo não mostrou qualquer melhora significativa nesses desfechos secundários. Esses resultados demonstraram a superioridade do estrogênio potencializado em comparação ao placebo. Alguns efeitos adversos foram associados com o estrogênio dinamizado. Conclusões: Estrogênio potencializado (12cH, 18cH e 24cH) na dose de 3 gotas 2 vezes ao dia durante 24 semanas foi significativamente mais eficaz que o placebo na redução da dor pélvica associada à endometriose.Registro do estudo: ClinicalTrials.gov Identificador: NCT02427386. (AU)

Potentized estrogen in homeopathic treatment of endometriosis-associated pelvic pain: A 24-week, randomized, double-blind, placebo-controlled study

OBJECTIVE: To evaluate the efficacy and safety of potentized estrogen compared to placebo in homeopathic treatment of endometriosis-associated pelvic pain (EAPP). Study design: The present was a 24-week, randomized, double-blind, placebocontrolled trial that included 50 women aged 18-45 years old with diagnosis of deeply infiltrating endometriosis based on magnetic resonance imaging or transvaginal ultrasound after bowel preparation, and score ≥ 5 on a visual analogue scale (VAS: range 0 to 10 points) for endometriosis-associated pelvic pain. Potentized estrogen (12cH, 18cH and 24cH) or placebo was administered twice daily per oral route. The primary outcome measure was change in the severity of EAPP global and partial scores (VAS) from baseline to week 24, determined as the difference in the mean score of five modalities of chronic pelvic pain (dysmenorrhea, deep dyspareunia, non-cyclic pelvic pain, cyclic bowel pain and/or cyclic urinary pain). The secondary outcome measures were mean score difference for quality of life assessed with SF-36 Health Survey Questionnaire, depression symptoms on Beck Depression Inventory (BDI), and anxiety symptoms on Beck Anxiety Inventory (BAI). RESULTS: The EAPP global score (VAS: range 0 to 50 points) decreased by 12.82 (p< 0.001) in the group treated with potentized estrogen from baseline to week 24. Group that used potentized estrogen also exhibited partial score (VAS: range 0 to 10 points) reduction in three EAPP modalities: dysmenorrhea (3.28; p< 0.001), non-cyclic pelvic pain (2.71; p= 0.009), and cyclic bowel pain (3.40; p< 0.001). Placebo group did not show any significant changes in EAPP global or partial scores. [...] CONCLUSIONS: Potentized estrogen (12cH, 18cH and 24cH) at a dose of 3 drops twice daily for 24 weeks was significantly more effective than placebo for reducing endometriosis-associated pelvic pain. Trial registration: ClinicalTrials.gov Identifier: https://clinicaltrials.gov/show/NCT02427386.

Algunas consideraciones sobre miasma y homeopatía / Some considerations on miasma and homeopathy

La medicina homeopática, disciplina capaz de ampliar el nivel de conocimiento con una óptica naturista, ayuda a elevar el dominio clínico y terapéutico de profesionales de la salud, a la vez que permite tener una visión más amplia del enfermo a partir de su integración consigo mismo y con el medio. El miasma en homeopatía es la alteración de la energía vital del individuo que lo predispone a padecer determinadas enfermedades. A tales efectos se realizó una revisión bibliográfica exhaustiva sobre el tema y se ofrece la interpretación de las definiciones antiguas relacionadas con la concepción actual. Todo lo anterior facilitará el diagnóstico diferencial entre los medicamentos homeopáticos que pueden ser utilizados

The homeopathic medicine, a discipline which widens the knowledge level with a naturist vision, helps to elevate the clinical and therapeutic control of the health professionals, at the same time that allows to have a wider vision of the patient taking into account his integration with himself and with the environment. Miasma in homeopathy is the alteration of the individual's vital energy that predisposes him to suffer certain illnesses. To such effects, an exhaustive literature review on the topic was carried out and the interpretation of the old definitions related to the current conception is offered. All the above-explained will facilitate the differential diagnosis among the homeopathic medications that can be used

Efectividad del tratamiento homeopático en pacientes con trastorno del sueño / Effectiveness of the homeopathic treatment in patients with sleeping disorder

Se realizó un estudio experimental, de tipo intervención terapéutica, en 48 pacientes con trastorno del sueño, atendidos en el Centro de Salud Mental del municipio de Contramaestre, de la provincia de Santiago de Cuba, desde enero hasta junio de 2015, con vistas evaluar la respuesta al tratamiento con homeopatía. Se conformaron 2 grupos de 24 integrantes cada uno: el primero recibió los beneficios de los remedios homeopáticos y el segundo, tratamiento convencional. Entre los resultados principales predominaron el trastorno ansioso (50,0 %) y el uso de la pasiflora (45,0 %). El tratamiento homeopático resultó ser tan efectivo como el convencional, la evolución clínica fue más rápida y no produjo reacciones adversas.

An experimental, of therapeutic intervention study type was carried out, in 48 patients with sleeping disorder, assisted in the Mental Health Center of Contramaestre, in Santiago de Cuba, from January to June, 2015, aimed at evaluating the response to the treatment with homeopathy. Two groups of 24 members each were formed: the first one received the benefits of the homeopathic remedies and the second, conventional treatment. Among the main results the anxious disorder (50.0%) and the use of passiflora (45.0%) prevailed. The homeopathic treatment was as effective as the conventional one, the clinical course was faster and it didn't produce adverse reactions.

Efectividad de remedios homeopáticos en niños operados de estrabismo / Effectiveness of homeopathic remedies in children operated for strabismus

Se realizó una intervención terapéutica en 100 pacientes operados de estrabismo, atendidos en la consulta oftalmológica del Hospital Infantil Sur de Santiago de Cuba, desde octubre del 2006 hasta igual periodo del 2013, a fin de evaluar la efectividad del tratamiento homeopático en ellos. Los afectados fueron divididos en 2 grupos de 50 integrantes cada uno: el de estudio, que recibió tratamiento homeopático, y el de control, tratado convencionalmente. No existió diferencia significativa en cuanto a la edad y el sexo en ambos grupos (p>0,5). Luego de aplicadas las terapias se obtuvo una efectividad marcada del tratamiento homeopático (96,0 %) en relación con el convencional, con una diferencia significativa entre ambos grupos p<0,5.

A therapeutical intervention in 100 patients operated of strabismus, assisted in the Ophthalmology Department of the Southern Children Hospital in Santiago de Cuba, was carried out from October, 2006 to the same period of 2013, in order to evaluate the effectiveness of the homeopathic treatment in them. The affected ones were divided in 2 groups of 50 members each: the study group which received homeopathic treatment, and the control group, treated conventionally. There was no significant difference as for age and sex in both groups (p>0.5). After applying the therapies a marked effectiveness of the homeopathic treatment was obtained (96.0%) in relation to the conventional one, with a significant difference between both groups p <0.5.

Efectividad del tratamiento homeopático en pacientes con síndrome depresivo / Effectiveness of the homeopathic treatment in patients with depressive syndrome

Se realizó un estudio experimental, de tipo intervención terapéutica, en 35 pacientes con síndrome depresivo, atendidos en el Centro de Desarrollo de la Medicina Natural y Tradicional del Hospital General Docente "Dr. Juan Bruno Zayas Alfonso" de Santiago de Cuba, desde agosto de 2010 hasta febrero de 2011, con vistas a determinar la efectividad de los remedios homeopáticos. En la serie predominaron las mujeres mayores de 35 años de edad (80,0 %), las enfermedades reumáticas y de la vía digestiva como antecedentes patológicos personales más comunes, acompañados de cansancio, fatiga y depresión, así como las alteraciones del sueño como síntomas psicológicos más frecuentes; asimismo, los remedios más usados resultaron ser: Natrum muriaticum, Aurum metallicum y Pulsatilla. La evolución favorable de los afectados puso de manifiesto la utilidad de esta terapia para disminuir la depresión.

An experimental study, of therapeutic intervention type was carried out in 35 patients with depressive syndrome, assisted in the Center of Development for Natural and Traditional Medicine at "Dr. Juan Bruno Zayas Alfonso" Teaching General Hospital in Santiago de Cuba, from August, 2010 to February, 2011, aimed at determining the effectiveness of the homeopathic remedies. In the series, women older than 35 years of age (80.0%), the rheumatic and digestive diseases as the most common pathological and personal histories prevailed, accompanied by fatigue, and depression, as well as the changes in sleep as the most frequent psychological symptoms; also, the most used remedies turned out to be: Natrum muriaticum, Aurum metallicum and Pulsatilla. The favorable clinical course of the affected patients showed the usefulness of this therapy to decrease depression.

Immunomodulatory drugs (natalizumab), worsening of multiple sclerosis, rebound effect and similitude.

BACKGROUND: Homeopathic treatment is based on the principle of similitude ('like cures like') administering to sick individuals substances that cause similar symptoms in healthy individuals, employing the paradoxical or biphasic action of the organism as therapeutic response. This homeostatic, vital or secondary action of the organism is scientifically explained by the rebound effect of drugs, resulting in worsening of symptoms after enantiopathic treatment withdrawal. Natalizumab reduces relapses in patients with active multiple sclerosis (MS), but recent studies report severe worsening of MS after suspension of treatment, as a consequence of the rebound effect. METHOD: Extending this source of evidence, this work reviews research that demonstrates secondary worsening of MS after discontinuation of natalizumab, a human monoclonal antibody that suppresses the disease inflammatory activity as primary action. RESULTS: Several studies refer to the immune reconstitution inflammatory syndrome (IRIS) as a plausible explanation of reactivation of MS after withdrawal of natalizumab: a rebound effect or secondary action of the organism in response to the primary immunosuppression caused by the drug. CONCLUSION: Relapses of MS after discontinuation of natalizumab treatment indicate rebound of disease activity, supporting the homeopathic principle and warning healthcare professionals about this serious iatrogenic event.

Ameliorating effect of mother tincture of Syzygium jambolanum on carbohydrate and lipid metabolic disorders in streptozotocin-induced diabetic rat: Homeopathic remedy.

BACKGROUND: Syzygium jambolanum (S jambolanum) is widely used in homeopathy for treating patients with diabetes mellitus. In the present study, an attempt has been made to investigate the remedial effect of homeopathic drug S jambolanum on carbohydrate and lipid metabolic disorders on streptozotocin induced diabetic rat. MATERIALS AND METHODS: Diabetes induction in Wistar strain rat was performed as per standard method using streptozotocin at the dose of 4 mg/100 gm body weight. Activities of carbohydrate metabolic enzymes in hepatic tissue, and glycogen content in hepatic and muscular tissues were assessed biochemically following the standard protocols. Serum lipid profile level and activities of GOT and GPT in serum were measured as per standard method using specific kits. RESULTS: The homeopathic drug, mother tincture of S jambolanum significantly decreased fasting blood glucose levels and improved carbohydrate metabolic key enzyme activities in hepatic tissue i.e., hexokinase, glucose-6-phosphate dehydrogenase and glucose-6-phosphatase in diabetic rats. Alongside, serum lipid profile biomarkers i.e., triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDLc), very low density lipoprotein cholesterol (VLDLc) and high density lipoprotein cholesterol (HDLc) levels were significantly ameliorated in homeopathic drug supplemented diabetic animals in compared with the untreated diabetic animal. Side by side, the S jambolanum has the capacity to attenuate diabetes induced hepatic injury in model animal, which has been assessed here by the recovery of GOT and GPT activities in serum of drug treated diabetic animal. CONCLUSION: The result of the present study indicated that the homeopathic drug S jambolanum (mother tincture) has a protective effect on diabetic induced carbohydrate and lipid metabolic disorders in STZ-induced diabetic animal.

Can homeopathy bring additional benefits to thalassemic patients on hydroxyurea therapy? Encouraging results of a preliminary study.

Several homeopathic remedies, namely, Pulsatilla Nigricans (30th potency), Ceanothus Americanus (both mother tincture and 6th potency) and Ferrum Metallicum (30th potency) selected as per similia principles were administered to 38 thalassemic patients receiving Hydroxyurea (HU) therapy for a varying period of time. Levels of serum ferritin (SF), fetal hemoglobin (HbF), hemoglobin (Hb), platelet count (PC), mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular hemoglobin (MCH), white blood cell (WBC) count, bilirubin content, alanine amino transferase (ALT), aspartate amino transferase (AST) and serum total protein content of patients were determined before and 3 months after administration of the homeopathic remedies in combination with HU to evaluate additional benefits, if any, derived by the homeopathic remedies, by comparing the data with those of 38 subjects receiving only HU therapy. Preliminary results indicated that there was a significant decrease in the SF and increase in HbF levels in the combined, treated subjects. Although the changes in other parameters were not so significant, there was a significant decrease in size of spleen in most patients with spleenomegaly and improvement in general health conditions along with an increased gap between transfusions in most patients receiving the combined homeopathic treatment. The homeopathic remedies being inexpensive and without any known side-effects seem to have great potentials in bringing additional benefits to thalassemic patients; particularly in the developing world where blood transfusions suffer from inadequate screening and fall short of the stringent safety standards followed in the developed countries. Further independent studies are encouraged.